Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sees no need to change its 2010 guidance based on health care reform and maintains its forecast for mid-single-digit growth.